SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 5, 2009--
Exelixis, Inc. (Nasdaq:EXEL) announced today that Michael Morrissey,
PhD, the company’s President of Research & Development, will present at
the Barclays Capital Global Healthcare Conference at 4:45 p.m. ET/1:45
p.m. PT on Tuesday, March 10, 2009. Dr. Morrissey will discuss the
company’s corporate strategy, financial outlook, and development
pipeline.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals,
and Daiichi-Sankyo. For more information, please visit the company’s web
site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Investor Contact:
Charles
Butler, 650-837-7277
Senior Director
Corporate
Communications
& Investor Relations
cbutler@exelixis.com
Media
Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior
Manager
Corporate Communications
sharrison@exelixis.com